Next Article in Journal
Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Next Article in Special Issue
Immunotherapy in Thoracic Malignancies: New Treatment and New Hope
Previous Article in Journal
Reproductive Health Experiences of Females Diagnosed with Young-Onset Colorectal Cancer: A Multi-Method Cross-Sectional Survey
Previous Article in Special Issue
New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 29
Issue 2
10.3390/curroncol29020043
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review

by
Raida M. Khwaja
and
Quincy S.-C. Chu
*
Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(2), 479-489; https://doi.org/10.3390/curroncol29020043
Submission received: 29 October 2021 / Revised: 5 January 2022 / Accepted: 17 January 2022 / Published: 21 January 2022
(This article belongs to the Special Issue Current State of Immunotherapy for Lung Cancer)
Browse Figures
Versions Notes

Abstract

Targeting the immune system, especially the PDL-1/PD-1 axis, has significantly improved the outcomes of metastatic lung cancer patients. However, only a portion of patients will benefit significantly from PD(L)1 therapeutics alone or in combination with either chemotherapy or anti-CTLA4 antibody. It is therefore important to study predictive biomarkers to help select the patients who will experience the most benefit from immunotherapy. In this paper, the current status of PDL-1 expression on tumour cells, the smoking status of patients, tumour mutational burden, gut microbiome and STK11 and KEAP1 mutations in the tumour as predictive biomarkers for PD(L)-1-based immunotherapy are summarized.
Keywords: PD(L)1; immunotherapy; predictive biomarkers; non-small cell lung cancer PD(L)1; immunotherapy; predictive biomarkers; non-small cell lung cancer

Share and Cite

MDPI and ACS Style

Khwaja, R.M.; Chu, Q.S.-C. Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. Curr. Oncol. 2022, 29, 479-489. https://doi.org/10.3390/curroncol29020043

AMA Style

Khwaja RM, Chu QS-C. Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. Current Oncology. 2022; 29(2):479-489. https://doi.org/10.3390/curroncol29020043

Chicago/Turabian Style

Khwaja, Raida M., and Quincy S.-C. Chu. 2022. "Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review" Current Oncology 29, no. 2: 479-489. https://doi.org/10.3390/curroncol29020043

APA Style

Khwaja, R. M., & Chu, Q. S.-C. (2022). Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. Current Oncology, 29(2), 479-489. https://doi.org/10.3390/curroncol29020043

Article Metrics

Back to TopTop